Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment

References

• Amorusi P, Lessard D, Bansal SK, et al. (1994). Analysis of enloplatin by liquid chromatography and of platinum by atomic absorption spectrometry in various biological fluids. J Pharm Biomed Anal 12:1023–33
   PubMed Web of Science ®Google Scholar
• Belani CP, Ramalingam S, Perry MC, et al. (2008). Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 26:468–73
   PubMed Web of Science ®Google Scholar
• Boulikas T. (2004). Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 12:3–12
   PubMed Web of Science ®Google Scholar
• Burger KN, Staffhorst RW, de Vijlder HC, et al. (2002). Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med 8:81–4
   PubMed Web of Science ®Google Scholar
• Butler JS, Sadler PJ. (2013). Targeted delivery of platinum-based anticancer complexes. Curr Opin Chem Bio 17:175–88
   PubMed Web of Science ®Google Scholar
• Chang WJ, Sun JM, Lee JY, et al. (2014). A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. Lung Cancer 84:51–5
   PubMed Web of Science ®Google Scholar
• Dai W, Jin W, Zhang J, et al. (2012). Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes. Pharm Res 29:2902–11
   PubMed Web of Science ®Google Scholar
• de Marinis F, Rossi A, Di Maio M, et al. (2011). Italian association of thoracic oncology. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 73:1–10
   PubMed Web of Science ®Google Scholar
• Dhar S, Kolishetti N, Lippard SJ, et al. (2011). Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 108:1850–5
   PubMed Web of Science ®Google Scholar
• Duan J, Mansour HM, Zhang Y, et al. (2012). Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 426:193–201
   PubMed Web of Science ®Google Scholar
• Fang YP, Lin YK, Su YH, et al. (2011). Tryptanthrin-loaded nanoparticles for delivery into cultured human breast cancer cells, MCF7: the effects of solid lipid/liquid lipid ratios in the inner core. Chem Pharm Bull (Tokyo) 59:266–71
   PubMed Web of Science ®Google Scholar
• Feazell RP, Nakayama-Ratchford N, Dai H, et al. (2007). Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc 129:8438–9
   PubMed Web of Science ®Google Scholar
• Gianni L, Munzone E, Capri G, et al. (1995). Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688–99
   PubMed Web of Science ®Google Scholar
• Gill KK, Kaddoumi A, Nazzal S. (2012). Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines. Eur J Pharm Sci 46:64–71
   PubMed Web of Science ®Google Scholar
• Hu CM, Zhang L. (2012). Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 83:1104–11
   PubMed Web of Science ®Google Scholar
• Jain K, Gupta U, Jain NK. (2014). Dendronized nanoconjugates of lysine and folate for treatment of cancer. Eur J Pharm Biopharm 87:500–9
   PubMed Web of Science ®Google Scholar
• Kelly K, Crowley J, Bunn PA Jr, et al. (2001). Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19:3210–18
   PubMed Web of Science ®Google Scholar
• Kolishetti N, Dhar S, Valencia PM, et al. (2010). Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 107:17939–44
   PubMed Web of Science ®Google Scholar
• McKeage MJ. (1995). Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228–44
   PubMed Web of Science ®Google Scholar
• Mittal A, Chitkara D, Kumar N. (2007). HPLC method for the determination of carboplatin and paclitaxel with cremophorEL in an amphiphilic polymer matrix. J Chromatogr B Analyt Technol Biomed Life Sci 855:211–19
   PubMed Web of Science ®Google Scholar
• Oberoi HS, Laquer FC, Marky LA, et al. (2011). Core cross-linked block ionomer micelles as pH-responsive carriers for cis-diamminedichloroplatinum(II). J Control Release 153:64–72
   PubMed Web of Science ®Google Scholar
• Oberoi HS, Nukolova NV, Kabanov AV, et al. (2013). Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 65:1667–85
   PubMed Web of Science ®Google Scholar
• Powell HA, Tata LJ, Baldwin DR, et al. (2014). Treatment decisions and survival for people with small-cell lung cancer. Br J Cancer 110:908–15
   PubMed Web of Science ®Google Scholar
• Rahman HS, Rasedee A, How CW, et al. (2013). Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect. Int J Nanomed 8:2769–81
   PubMed Web of Science ®Google Scholar
• Rice JR, Gerberich JL, Nowotnik DP, et al. (2006). Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res 12:2248–54
   PubMed Web of Science ®Google Scholar
• Satouchi M, Okamoto I, Sakai H, et al. (2013). Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 81:97–101
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M, et al. (2002). Italian lung cancer project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285–91
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. (2002). Eastern cooperative oncology group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–8
   PubMed Web of Science ®Google Scholar
• Shin HC, Alani AW, Cho H, et al. (2011). A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol Pharm 8:1257–65
   PubMed Web of Science ®Google Scholar
• Shiah JG, Sun Y, Kopecková P, et al. (2001). Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates. J Control Release 74:249–53
   PubMed Web of Science ®Google Scholar
• Socinski MA. (2014). Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. Curr Oncol 21:e691–703
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Boulikas T. (2012). Lipoplatin formulation review article. J Drug Deliv 2012:581363
   PubMedGoogle Scholar
• Ulukaya E, Ozdikicioglu F, Oral AY, et al. (2008). The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol In Vitro 22:232–9
   PubMed Web of Science ®Google Scholar
• Vasey PA, Paul J, Birt A, et al. (1999). Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol 17:2069–80
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang L, Peng H, et al. (2013). The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. Mater Sci Eng C Mater Biol Appl 33:4802–8
   PubMed Web of Science ®Google Scholar
• Xiao H, Li W, Qi R, et al. (2012). Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy. J Control Release 163:304–14
   PubMed Web of Science ®Google Scholar
• Xu X, Xie K, Zhang XQ, et al. (2013). Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci USA 110:18638–43
   PubMed Web of Science ®Google Scholar
• Zhang K, Tang X, Zhang J, et al. (2014). PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications. J Control Release 183:77–86
   PubMed Web of Science ®Google Scholar